Clin Cancer Res (2003) 9(6):220412
Tirzepatide is a newer dual GLP-1 and GIP receptor agonist approved by the FDA in 2022, representing the next evolution after single GLP-1 drugs
Currently incurable, relapse and drug resistance remain significant challenges, necessitating the exploration of novel anti-MM agents
For instance, in studies involving high doses of NAC, researchers observed promising outcomes in neuroprotection, including a significant reduction in striatal lesion volumes in a rat model of Huntingtons disease
(2020) Grow All You Can, And Save All You Grow: Innovation and Tradition at the Prince Edward County Community Cannery. MA thesis, Department of American Studies, University of North Carolina at Chapel Hill
Key exclusion criteria included diabetes, hemoglobin A 1c (HbA 1c ) level of 6.5% (48 mmol/mol) or greater, and self-reported body weight changes of more than 5 kg 90 days or less before screening